BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 2544850)

  • 1. Adverse reactions and serologic response to a booster dose of acellular pertussis vaccine in children immunized with acellular or whole-cell vaccine as infants.
    Blennow M; Granström M
    Pediatrics; 1989 Jul; 84(1):62-7. PubMed ID: 2544850
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose-response to a two-component acellular pertussis vaccine in infants and comparison with whole-cell vaccine.
    Auerbach BS; Lake AM; Wilson ME; Willingham FF; Shematek J; Moulton L; Deforest A; Halsey NA
    Biologicals; 1998 Jun; 26(2):145-53. PubMed ID: 9811522
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary immunization of infants with an acellular pertussis vaccine in a double-blind randomized clinical trial.
    Blennow M; Granström M; Jäätmaa E; Olin P
    Pediatrics; 1988 Sep; 82(3):293-9. PubMed ID: 3043367
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of nine candidate DTP-vaccines with reduced amount of antigen and/or without adjuvant as a fourth (booster-) dose in the second year of life.
    Knuf M; Habermehl P; Faber J; Bock HL; Sänger R; Bogaerts H; Clemens R; Schuind A; du Prel JB; Schmitt HJ
    Vaccine; 2006 Jul; 24(27-28):5627-36. PubMed ID: 16740348
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differences of humoral and cellular immune response to an acellular pertussis booster in adolescents with a whole cell or acellular primary vaccination.
    Rieber N; Graf A; Belohradsky BH; Hartl D; Urschel S; Riffelmann M; Wirsing von König CH; Liese J
    Vaccine; 2008 Dec; 26(52):6929-35. PubMed ID: 18852002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An open study evaluating the reactogenicity and immunogenicity of a DTP vaccine containing an acellular pertussis component in four to six year old children.
    Lewis K; Cherry JD; Baraff LJ; Robinson RG; Dudenhoeffer FE; Holroyd HJ; Baker LR; Farchione SL; Gurwith M; Vernon S
    Dev Biol Stand; 1985; 61():563-9. PubMed ID: 2872132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and immunogenicity of an acellular pertussis vaccine booster in 15- to 20-month-old children previously immunized with acellular or whole-cell pertussis vaccine as infants.
    Pichichero ME; Francis AB; Marsocci SM; Green JL; Disney FA; Meschievitz C
    Pediatrics; 1993 Apr; 91(4):756-60. PubMed ID: 8464662
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Tolerance of acellular pertussis vaccine booster injection in 15-20-month-old children].
    Mallet E; Puyt A; Arson S; Surbled V
    Arch Pediatr; 2000 Apr; 7(4):410-4. PubMed ID: 10793931
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diphtheria and tetanus toxoids and pertussis vaccine adsorbed (DTP): response to varying immunizing dosage and schedule.
    Barkin RM; Samuelson JS; Gotlin LP
    Dev Biol Stand; 1985; 61():297-307. PubMed ID: 2872117
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of changing from whole-cell to acellular pertussis vaccine on the epidemiology of hospitalized children with pertussis in Canada.
    Bettinger JA; Halperin SA; De Serres G; Scheifele DW; Tam T
    Pediatr Infect Dis J; 2007 Jan; 26(1):31-5. PubMed ID: 17195702
    [TBL] [Abstract][Full Text] [Related]  

  • 11. One-year post-primary antibody persistence and booster immune response to a fully liquid five-component acellular pertussis, diphtheria, tetanus, inactivated poliomyelitis, Haemophilus influenzae type b conjugate vaccine.
    Lin TY; Wang YH; Huang YC; Chiu CH; Lin PY; Chen CJ; Chavand P; Ortiz E
    Int J Infect Dis; 2007 Nov; 11(6):488-95. PubMed ID: 17349809
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acellular pertussis vaccine as a booster dose for seventeen- to nineteen-month-old children immunized with either whole cell or acellular pertussis vaccine at two, four and six months of age.
    Halperin SA; Mills E; Barreto L; Pim C; Eastwood BJ
    Pediatr Infect Dis J; 1995 Sep; 14(9):792-7. PubMed ID: 8559630
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized clinical trial of acellular pertussis vaccines in healthy adults: dose-response comparisons of 5 vaccines and implications for booster immunization.
    Keitel WA; Muenz LR; Decker MD; Englund JA; Mink CM; Blumberg DA; Edwards KM
    J Infect Dis; 1999 Aug; 180(2):397-403. PubMed ID: 10395855
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity, reactogenicity and safety of a 7-valent pneumococcal conjugate vaccine (PCV7) concurrently administered with a DTPa-HBV-IPV/Hib combination vaccine in healthy infants.
    Knuf M; Habermehl P; Cimino C; Petersen G; Schmitt HJ
    Vaccine; 2006 May; 24(22):4727-36. PubMed ID: 16616973
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pertussis-specific cell-mediated and humoral immunity in adolescents 3 years after booster immunization with acellular pertussis vaccine.
    Edelman KJ; He Q; Makinen JP; Haanpera MS; Tran Minh NN; Schuerman L; Wolter J; Mertsola JA
    Clin Infect Dis; 2004 Jul; 39(2):179-85. PubMed ID: 15307026
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A modified schedule for routine pertussis immunization.
    Swartz TA; Roumiantzeff M; Peyron L; Stopler T; Kanaaneh H; Leitner L; Goldblum N
    Dev Biol Stand; 1985; 61():289-96. PubMed ID: 2872116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Results with a new DTP vaccine in Japan.
    Kimura M; Hikino N
    Dev Biol Stand; 1985; 61():545-61. PubMed ID: 2872131
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term follow-up of Swedish children vaccinated with acellular pertussis vaccines at 3, 5, and 12 months of age indicates the need for a booster dose at 5 to 7 years of age.
    Gustafsson L; Hessel L; Storsaeter J; Olin P
    Pediatrics; 2006 Sep; 118(3):978-84. PubMed ID: 16950988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Booster response to acellular pertussis vaccine in children primed with acellular or whole cell vaccines.
    Edwards KM; Decker MD; Bradley RB; Taylor JC; Hager CC
    Pediatr Infect Dis J; 1991 Apr; 10(4):315-8. PubMed ID: 2062628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pertussis booster vaccination in HIV-infected children receiving highly active antiretroviral therapy.
    Abzug MJ; Song LY; Fenton T; Nachman SA; Levin MJ; Rosenblatt HM; Pelton SI; Borkowsky W; Edwards KM; Peters J;
    Pediatrics; 2007 Nov; 120(5):e1190-202. PubMed ID: 17938165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.